These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 15799093)

  • 41. Efavirenz + emtricitabine + tenofovir: new combination. HIV infection: do not modify ongoing therapy just to use one less tablet. Better adherence than with separate dosing has not been demonstrated, while reduced efficacy is plausible.
    Prescrire Int; 2009 Jun; 18(101):105. PubMed ID: 19637416
    [No Abstract]   [Full Text] [Related]  

  • 42. Promising new agents on the horizon.
    Feinberg J
    AIDS Clin Care; 2002 Mar; 14(3):22. PubMed ID: 12141239
    [No Abstract]   [Full Text] [Related]  

  • 43. Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence.
    McAllister J; Read P; McNulty A; Tong WW; Ingersoll A; Carr A
    HIV Med; 2014 Jan; 15(1):13-22. PubMed ID: 24007390
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Acute renal failure, Fanconi syndrome and insipidus diabetes in a HIV-infected patient treated with Tenofovir].
    Harmouche H; Le Bras P; Bignani O; Delfraissy JF; Goujard C
    Rev Med Interne; 2005 Jun; 26(6):522-3. PubMed ID: 15936484
    [No Abstract]   [Full Text] [Related]  

  • 45. European Commission approves Atripla.
    AIDS Patient Care STDS; 2008 Jan; 22(1):87-8. PubMed ID: 18453042
    [No Abstract]   [Full Text] [Related]  

  • 46. [Tenofovir in Study 903. Also effective and tolerable in first-line therapy].
    MMW Fortschr Med; 2002 Aug; 144(33-34):61. PubMed ID: 12380158
    [No Abstract]   [Full Text] [Related]  

  • 47. Abacavir/3TC vs. tenofovir/FTC: interim results from ACTG 5202.
    Albrecht H
    AIDS Clin Care; 2008 Apr; 20(4):28. PubMed ID: 19271262
    [No Abstract]   [Full Text] [Related]  

  • 48. Trial of antiretroviral for HIV prevention on hold.
    Ahmad K
    Lancet Infect Dis; 2004 Oct; 4(10):597. PubMed ID: 15470760
    [No Abstract]   [Full Text] [Related]  

  • 49. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R; Calza L
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Many in VOICE trial didn't use provided prevention products.
    AIDS Policy Law; 2015 Mar; 30(4):3. PubMed ID: 26094276
    [No Abstract]   [Full Text] [Related]  

  • 51. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study).
    Ribera E; Paradiñeiro JC; Curran A; Sauleda S; García-Arumí E; Castella E; Puiggròs C; Crespo M; Feijoo M; Diaz M; Del Saz SV; Planas M; Sureda D; Falcó V; Ocaña I; Pahissa A
    HIV Clin Trials; 2008; 9(6):407-17. PubMed ID: 19203906
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Report from the 13th retrovirus conference. Renal tenofovir debate continues.
    Nagy GS
    AIDS Clin Care; 2006 Apr; 18(4):37-8. PubMed ID: 16718881
    [No Abstract]   [Full Text] [Related]  

  • 53. AIDS research. New drug shows promise in monkeys.
    Cohen J
    Science; 1995 Nov; 270(5239):1121-2. PubMed ID: 7502035
    [No Abstract]   [Full Text] [Related]  

  • 54. Compassionate use for tenofovir.
    AIDS Patient Care STDS; 2000 Feb; 14(2):101-2. PubMed ID: 10743524
    [No Abstract]   [Full Text] [Related]  

  • 55. Second tenofovir phase III study for the chronic HBV reaches primary endpoint.
    AIDS Patient Care STDS; 2007 Aug; 21(8):607-8. PubMed ID: 17907310
    [No Abstract]   [Full Text] [Related]  

  • 56. Elvucitabine data released at CROI.
    AIDS Patient Care STDS; 2010 Mar; 24(3):198. PubMed ID: 20235383
    [No Abstract]   [Full Text] [Related]  

  • 57. Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview.
    Bartlett JA; Chen SS; Quinn JB
    HIV Clin Trials; 2007; 8(4):221-6. PubMed ID: 17720662
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of Tenofovir gel as a PrEP on HIV infection: a mathematical model.
    Rahman SM; Vaidya NK; Zou X
    J Theor Biol; 2014 Apr; 347():151-9. PubMed ID: 24380779
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
    Gallant JE; Rodriguez AE; Weinberg WG; Young B; Berger DS; Lim ML; Liao Q; Ross L; Johnson J; Shaefer MS;
    J Infect Dis; 2005 Dec; 192(11):1921-30. PubMed ID: 16267763
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adefovir for the treatment of HIV infection: if not now, when?
    Mellors JW
    JAMA; 1999 Dec 22-29; 282(24):2355-6. PubMed ID: 10612325
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.